Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


Because of the potential adverse events and teratogenesis of antipsychotic drugs, it is important to find a safe and effective treatment for pregnant women with severe mental illness. The membrane hypothesis of schizophrenia provides a rationale to treat symptoms of schizophrenia with omega-3 PUFAs. We report a 30-year-old married woman with chronic schizophrenia, who experienced an episode of acute exacerbation of psychotic symptoms during pregnancy. After entering into an open trial of omega-3 PUFAs monotherapy, she showed a dramatic improvement in both positive and negative symptoms of schizophrenia and a significant increase of omega-3 PUFA composition in erythrocyte membrane. There were no adverse effects in this treatment. Thus, omega-3 PUFAs could be both beneficial and therapeutic to pregnant schizophrenic women.

Original languageEnglish
Pages (from-to)295-299
Number of pages5
JournalEuropean Neuropsychopharmacology
Issue number4
Publication statusPublished - 2001


  • Docosahexaenoic acid (DHA)
  • Ecosapentaenoic acid (EPA)
  • Omega-3 polyunsaturated fatty acids (PUFAs)
  • Pregnancy
  • Schizophrenia
  • Teratogenesis

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)


Dive into the research topics of 'Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient'. Together they form a unique fingerprint.

Cite this